Subtype
Uterine Corpus Soft Tissue Neoplasm
CI-CAN-00001634Explore in graph →
Non-malignant46 active trials
- NCIt
- C40179
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001634Explore in graph →
Clinical trials
359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03317795 | Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids | completed | Phase 4 | 18 | Shannon K. Laughlin-TommasoOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT04030182 | Vitamin D Deficit in Women With Uterine Fibroids | completed | — | 127 | Instituto Mexicano del Seguro SocialOTHER_GOV | 1 | Nov 8, 2021 | clinicaltrials |
| NCT04672421 |
| The Efficacy and Safety of Medicurtain® in Patients With Total Laparoscopic Hysterectomy (Pivotal Study) |
| completed |
| N/A |
| 107 |
| Shin Poong Pharmaceutical Co. Ltd.INDUSTRY |
| 1 |
| Sep 29, 2021 |
| clinicaltrials |
| NCT04819633 | Evaluating Serum Sestrin in Leiomyoma Patients | completed | — | 61 | Sisli Hamidiye Etfal Training and Research HospitalOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT00731341 | Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata | completed | N/A | 3 | Boston Scientific CorporationINDUSTRY | 1 | Jul 19, 2021 | clinicaltrials |
| NCT01441635 | Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids | completed | Phase 2 | 271 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jul 13, 2021 | clinicaltrials |
| NCT02925494 | An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 433 | AbbVieINDUSTRY | 3 | Jul 13, 2021 | clinicaltrials |
| NCT03070899 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 1) | completed | Phase 3 | 526 | ObsEva SAINDUSTRY | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04832906 | UA Versus UAE in Treatment of Fibroids | completed | Phase 4 | 70 | Ain Shams Maternity HospitalOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 2) | completed | Phase 3 | 511 | ObsEva SAINDUSTRY | 9 | Mar 5, 2021 | clinicaltrials |
| NCT03021720 | Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial(SPARQLE) | completed | N/A | 40 | Mount Sinai Hospital, CanadaOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT03444987 | The Role of Fibroblast Activation in Uterine Fibroid | completed | — | 35 | Assiut UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT01840124 | Uterine Leiomyoma Treatment With Radiofrequency Ablation(ULTRA) | completed | N/A | 26 | University of California, San FranciscoOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT02260752 | Patient Centered Results for Uterine Fibroids(COMPARE-UF) | completed | — | 3,094 | Duke UniversityOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT03744507 | Bone Mineral Density in Women With Uterine Fibroids or Endometriosis | completed | — | 660 | Myovant Sciences GmbHINDUSTRY | 7 | Nov 10, 2020 | clinicaltrials |
| NCT04576039 | Ultrasonographic Appearance of the Endometrium After Ulipristalacetate Use and Endometrial Changes | completed | N/A | 10 | Universitair Ziekenhuis BrusselOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03535610 | Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.(EMBOSOFT I) | completed | N/A | 32 | Scitech Produtos Medicos SAINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03270605 | Myomectomy During CS: A Retrospective Cohort Study | completed | — | 178 | Mansoura UniversityOTHER | 0 | Sep 1, 2020 | clinicaltrials |
| NCT01817530 | Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) | completed | Phase 2 | 571 | AbbVieINDUSTRY | 0 | Jul 21, 2020 | clinicaltrials |
| NCT01846520 | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | completed | N/A | 200 | City of Hope Medical CenterOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03328260 | High Intensity Focused Ultrasound in Uterine Myoma | completed | N/A | 34 | Seoul National University HospitalOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT03411980 | Pharmacokinetics and Safety of Vilaprisan in Renal Impairment | completed | Phase 1 | 26 | BayerINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02096783 | Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer | completed | N/A | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02470741 | Pilot of Letrozole for Uterine Myomas(PLUM) | completed | Phase 4 | 12 | University of California, San FranciscoOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01377519 | Magnetic Resonance Guided Focused Ultrasound for Uterine Fibroids(PROMISe) | completed | N/A | 20 | University of California, San FranciscoOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT02844920 | Evaluation of Uterine Patency Following Sonography-guided Transcervical Ablation of Fibroids(OPEN) | completed | — | 37 | GynesonicsINDUSTRY | 4 | Sep 20, 2019 | clinicaltrials |
| NCT04091529 | Tailored Radiofrequency Ablation of Uterine Myomas | completed | N/A | 54 | International Evangelical HospitalOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT03427671 | OCL 500 Treatment of Women With Symptomatic Uterine Fibroids | completed | N/A | 12 | IMBiotechnologies Ltd.INDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT01168232 | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01220609 | Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01247571 | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00339547 | Risk Factors for Uterine Fibroids: A Case Control Study | completed | — | 1,529 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00025506 | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00075400 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025220 | Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00378911 | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01637961 | Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02889848 | Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids) | completed | Phase 1 | 15 | Advance Biofactures CorporationINDUSTRY | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | completed | Phase 2 | 42 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 25, 2019 | clinicaltrials |
| NCT00958334 | Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | completed | Phase 2 | 65 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00341848 | Postpartum Uterine Regression | completed | — | 374 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03072446 | Uterine Fibroid Embolization (UFE) for Symptomatic Fibroids: Comparison of Gel-Bead to Commonly Used Embolic Agents. | completed | N/A | 11 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | completed | Phase 3 | 65 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | completed | Phase 3 | 281 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT01142791 | Safety Study of ExAblate for the Treatment of Uterine Fibroids | completed | N/A | 121 | InSightecINDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 8, 2021source: clinicaltrials